Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2009

01.09.2009 | Original Article

Pregnancy outcome in pituitary tumors

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

To observe the maternal and perinatal outcome in pituitary tumor (macro- and micro-adenoma) during pregnancy.

Methods

A retrospective analysis of a total of 19 cases of pituitary tumor group 1 (10 macroadenoma), and group 2 (9 microadenoma), during pregnancy over last 3 years in our unit were evaluated for pregnancy outcome, comparing maternal and perinatal outcome in the two groups using statistical analysis (Chi square test and Fischer exact t test).

Results

The mean age was 27.1 years in group 1 (macroadenoma), 29.2 years in group, parity was 0.2 and 0.55, respectively, in the two groups. Mean pituitary size 14.85 cm3 in group 1 and 0.22 cm3 in group 2. While there was no significant difference in infertility, menstrual disorder in the two groups, galactorrhea, headache, seizures and blurring of vision were more common in macroadenoma group. More patients required medications (cabergoline/bromocriptine) in group 1 with significantly more women had worsening of their symptoms (raised intracranial tension, seizures) in group 1 than in group 2. Mean gestation and birthweight were better in group 2 (37.6 vs. 36.1 weeks and 2,849 vs. 2,401 g). While vaginal delivery could be achieved in 88.8% women in microadenoma group (group 2), 80% women required cesarean delivery in macroadenoma group (group 1), a highly significant difference (P value 0.005), there were no perinatal death in any group.

Conclusion

Pituitary tumor during pregnancy if properly treated is associated with excellent maternal and perinatal outcome but macroadenoma is associated with lower gestation, birth weight and increased cesarean delivery rate.
Literatur
2.
Zurück zum Zitat Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin N Am 35:99–116CrossRef Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin N Am 35:99–116CrossRef
3.
Zurück zum Zitat Goluboff LG, Ezrin C (1969) Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 29:1533–1538PubMedCrossRef Goluboff LG, Ezrin C (1969) Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 29:1533–1538PubMedCrossRef
4.
Zurück zum Zitat Rigg LA, Lein A, Yen SSC (1977) Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 129:454–456PubMed Rigg LA, Lein A, Yen SSC (1977) Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 129:454–456PubMed
5.
Zurück zum Zitat Ruiz-Velasco V, Tolis G (1984) Pregnancy in hyperprolactinemic women. Fertil Steril 41:793–805PubMed Ruiz-Velasco V, Tolis G (1984) Pregnancy in hyperprolactinemic women. Fertil Steril 41:793–805PubMed
6.
Zurück zum Zitat Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. J Am Med Assoc 247:1589–1591CrossRef Turkalj I, Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. J Am Med Assoc 247:1589–1591CrossRef
7.
Zurück zum Zitat Crosignani PG, Mattei AM, Sevcrini V, Cavioni V, Maggioni P, Testa G (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. J Obstet Gynecol Reprod Biol 44:175–180CrossRef Crosignani PG, Mattei AM, Sevcrini V, Cavioni V, Maggioni P, Testa G (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. J Obstet Gynecol Reprod Biol 44:175–180CrossRef
8.
10.
Zurück zum Zitat Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2007) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Horumon To Rinsho 68:66–71 Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2007) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Horumon To Rinsho 68:66–71
11.
Zurück zum Zitat Elster AD, Sanders TG, Vines FS, Chen MYM (1991) Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology 181:531–535PubMed Elster AD, Sanders TG, Vines FS, Chen MYM (1991) Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology 181:531–535PubMed
13.
Zurück zum Zitat Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) ls pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4:910–912PubMed Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) ls pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4:910–912PubMed
14.
Zurück zum Zitat Molitch ME (1992) Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 21:877–901PubMed Molitch ME (1992) Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 21:877–901PubMed
15.
Zurück zum Zitat Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1364–1370PubMed Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1364–1370PubMed
16.
Zurück zum Zitat Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146:935–938PubMed Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146:935–938PubMed
18.
Zurück zum Zitat Visot A (2001) Neurosurgery and pituitary tumors: surgical indications and outcome. Presse Med 30(8):401–404PubMed Visot A (2001) Neurosurgery and pituitary tumors: surgical indications and outcome. Presse Med 30(8):401–404PubMed
Metadaten
Titel
Pregnancy outcome in pituitary tumors
Publikationsdatum
01.09.2009
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0917-8

Weitere Artikel der Ausgabe 3/2009

Archives of Gynecology and Obstetrics 3/2009 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.